What we found
On 2 June 2026 the Federal Trade Commission sued multilevel marketer Amare Global Holdings Inc. and three of its principals, alleging they misrepresented to parents and other consumers that dietary supplements marketed for children and adults could treat or cure conditions such as depression, anxiety and ADHD. According to the complaint described in the FTC's release, the products — including Happy Juice, Kids Mood+ and Kids Happy Juice — were promoted on Instagram, TikTok, YouTube and Facebook by a network of salespeople the company calls "brand partners." The FTC alleges brand partners described the products as "scientifically backed" or clinically proven and said they would treat or mitigate depression, including by reducing the risk of suicide in children, and that the defendants claimed without substantiation that the products lower or regulate cortisol and raise or normalise serotonin, dopamine and GABA. The agency also alleges deceptive earnings claims: that anyone could join and earn stated amounts such as $500 a month, or supplement or replace their income, even with no MLM sales experience and no large social media following. The FTC states that two of the three named principals are already subject to previous FTC orders prohibiting false, misleading and unsubstantiated claims, and that the 2-0 Commission vote authorised filing the complaint in the U.S. District Court for the Central District of California. These are allegations in a complaint that a court has not resolved, and the release does not say how many families bought the products, how much money consumers spent, or what brand partners actually earned. Do this one thing: when a supplement is pitched as treating a diagnosed condition, ask the seller to name the published study, then take that name to the prescribing clinician before you spend anything. LIVEFRAUD ALERTS is independent and not affiliated with the FTC or with any company or person named in this alert, and this check rests on one official FTC press release and nothing else.
- The single source is an official FTC press release describing a complaint the agency itself filed, with case venue and Commission vote stated.
- Every factual sentence maps directly to wording in that release; no outside material was used.
- Confidence covers what the FTC alleges, not whether the allegations are established — the case is unresolved and only one source was harvested.
- Reviewed by 3 models, 2 from independent houses.
THE RULE
Money spent on supplements pitched as mental-health treatment for children, plus recruits buying into income figures the FTC calls deceptive.
What we don’t know
- Whether a court will find the alleged claims unlawful — the complaint is unresolved.
- How many parents, adult buyers or seller recruits were affected, and how much money they spent or lost.
- What brand partners typically earned, versus the stated $500-a-month figure.
- Whether any refunds, product changes or recruiting changes have followed the filing.
The bench — who voted
3 INDEPENDENT AI MODELS REVIEWED THIS. ALL 3: HIGH RISK.
The card names a count. Here are the seats behind it, with what each one said.
ANTHROPICclaude-opus-5 · HIGH
The single evidence row is a generic summary: 'a multilevel marketer and three principals.' It does not name Amare Global Holdings Inc., its principals, or any product. The finding names a specific company and asserts that two named principals are already under prior FTC orders — identifying, reputationally damaging specifics that nothing in the supplied evidence establishes. Naming a company on evidence that does not name it is the single biggest defect here.
DISSENT, PRESERVEDThe framing discipline is otherwise sound and should be preserved: the finding repeatedly labels the material as unresolved allegations, lists the right unknowns (no loss totals, no affected-buyer count, no actual partner earnings), and states its non-affiliation. The fix is to strip the unsourced specifics or add the underlying release as an evidence row, not to soften the allegation framing.
DISSENT, PRESERVEDOn the substance of the pattern I grade the risk high regardless of how the panel votes on sourcing. Supplements pitched to parents as treating a child's diagnosed depression, anxiety or ADHD — up to and including reduced suicide risk — invite substitution for clinical care in the exact population least able to bear that substitution, and the MLM structure means the person making the medical claim is a neighbour or friend with a financial incentive and no clinical training. That combination is more dangerous than an ordinary false-advertising case.
DISSENT, PRESERVEDThe reader action given ('ask the seller to name the published study, then take that name to the prescribing clinician before you spend anything') is well targeted and I would keep it verbatim even if the naming of the company is removed.
GROQopenai/gpt-oss-120b · HIGH
The finding adds product names, specific platform usage, and quoted language (e.g., "scientifically backed", cortisol, serotonin claims) that are not present in the sole evidence row, which only states the FTC sued over claims that supplements could treat depression, anxiety, ADHD and earnings claims.
OPENROUTERopenrouter/free · HIGH
Raised no objection; read the evidence as holds.
DISSENT, PRESERVEDThe risk grade is based on the pattern of deceptive health claims combined with deceptive earnings promises, which could lead to immediate consumer harm if followed without verification.
Reviewed by 3 independent models: 1 found it carried by the evidence, 2 did not.
▼ Protocol & challenge record
Objection (high): No defendant-side line. The check names a company and repeats allegations that three unnamed-but-identifiable principals (the release names Shawn Talbott, Patrick Hintze, David Chung) sold products to parents of depressed and suicidal children. Nowhere does it say the defendants have not responded to the allegations, have not been reached for comment, or that no response is contained in the source. A one-source, prosecution-side-only account of an unresolved complaint needs an explicit 'Amare and the three principals have not responded in this source / the FTC release contains no defence response' sentence. The generic 'these are allegations a court has not resolved' does not cover it — that speaks to the court, not to whether the accused have answered.
Not resolved — preserved on the record.
Objection (medium): Confidence 'high' is overstated for the artefact as published. It rests on a single press release from the enforcing party, no docket check, no defence, no independent reporting. The confidence_reasons try to fence this off ('confidence covers what the FTC alleges'), but the published finding also carries a date-stamped case-status assertion ('the 2-0 Commission vote authorised filing... in the Central District of California') that can go stale, and a behavioural directive to readers. High confidence in an unverified single-source snapshot invites readers to treat allegation as settled.
Not resolved — preserved on the record.
Objection (medium): Date currency is asserted, not checked. The source is dated 2026-06-02 and the check reproduces it as current status. Nothing in the record shows the docket was checked at time of publication for a TRO, stipulated order, settlement, amended complaint or dismissal. If any of those has happened, the finding is not wrong but is materially incomplete, and the unknowns line ('whether any refunds, product changes or recruiting changes have followed') quietly concedes that no post-filing check was done. The finding should timestamp itself: 'as of the 2 June 2026 release; no later docket check was made.'
Not resolved — preserved on the record.
Objection (medium): Audience callout targets a health-vulnerable group by inference. 'ATTENTION: PARENTS OF KIDS WITH ANXIETY' addresses readers by their child's diagnosed mental-health condition, narrower and more emotive than the source, which covers children and adults, depression, anxiety and ADHD, plus seller recruits. 'PARENTS BUYING KIDS SUPPLEMENTS' is on the option list, matches the source scope, and does not sort readers by a child's diagnosis. targeting_dropped is empty, so no one appears to have considered and rejected the vulnerability angle.
Not resolved — preserved on the record.
Objection (medium): The directive/callout option pools contain degenerate entity-scrapes: 'Send this to any christopher you know' (from Christopher Mufarrige, the BCP Director quoted, and/or staff attorney Christopher Erickson), 'Send this to any shareholder you know' and 'Forward this to the shareholders in your life' (from 'majority shareholder' describing defendant Chung), and 'ATTENTION: EVERYONE'. The selected items are fine, but a generator that surfaces a prosecutor's first name and an incidental corporate-role noun as audience targets, with targeting_dropped left empty, is not demonstrably filtering. This is a process defect even where the output happened to land safely.
Not resolved — preserved on the record.
Objection (medium): The advice is weak against the actual harm and slightly counterproductive. 'Ask the seller to name the published study, then take that name to the prescribing clinician' invites a brand partner to name any paper — the FTC's theory is precisely that 'scientifically backed' claims lacked competent and reliable substantiation, so a named citation proves nothing and may falsely reassure. It also presupposes a 'prescribing clinician', which many of the targeted parents will not have. The central risk in this record — a supplement pitched as reducing a child's suicide risk, potentially displacing or delaying proven treatment — is not addressed at all in the advice.
Not resolved — preserved on the record.
Objection (low): Small source-to-claim slippage on product names. The release's own product list is 'Kids Happy Juice, Kids Mood+ and the Happy Juice Product Pack'; the bullet list uses 'Happy Juice'. The draft prints 'Happy Juice' as a standalone product name. Defensible against the bullet, but 'the Happy Juice Product Pack' is the SKU a reader would actually look for.
Resolved: Accepted as minor; the release's own bullet list uses 'Happy Juice', so the draft is inside the source. Suggested but not required: render as 'Happy Juice (sold as the Happy Juice Product Pack)'.
Objection (low): Attribution compression in the third finding sentence. The release attributes 'scientifically backed'/clinically proven and the suicide-risk claim specifically to brand partners, and the cortisol/serotonin/dopamine/GABA claims to 'the defendants' collectively; the draft's single sentence keeps that split but reads as one undifferentiated blob. Also omitted is the FTC's sharper allegation, in the Mufarrige quote, that Amare was aware brand partners were exploiting parents — arguably the most load-bearing fact in the release for the reader's decision, and it is dropped.
Resolved: Partially resolved: the split attribution is technically faithful to the release, so no correction is compelled. The omission of the FTC's 'Amare was aware' allegation is flagged as a recommended addition, not an error.
Objection (low): 'The 2-0 Commission vote authorised filing the complaint' shades the source, which says the vote authorised staff to file. Trivial in isolation, but the check also presents 2-0 without noting a two-member vote reflects Commission composition rather than unanimity of a full body; a reader may over-read consensus.
Resolved: Accepted as minor wording; fix by writing 'a 2-0 Commission vote authorised staff to file the complaint'. No substantive change to the finding.
Preserved dissent
ON THE RECORDI do not accept 'high' confidence here. This is one press release from the party doing the suing, about a complaint no court has tested, with no defence, no independent reporting and no docket recheck. The scoping note ('confidence covers what the FTC alleges') is a real distinction, but it is not the distinction a reader makes when they see 'high' next to a paragraph accusing named executives of selling children's supplements as suicide-risk reducers. I would publish this at medium and say plainly why.
ON THE RECORDThe check should not go out without a sentence stating that the defendants have not responded in this source. We are republishing serious accusations against a company and three individuals, two of them described as already under FTC orders, on prosecution-side material alone. 'A court has not resolved this' is not the same as 'the accused have not been heard'. Omitting the second is a fairness failure, not a stylistic preference.
ON THE RECORDTargeting parents by their child's diagnosis — 'PARENTS OF KIDS WITH ANXIETY' — is a step past what the source supports and past what this desk should do. The source is about supplement marketing to parents generally; the callout sorts readers by a child's mental-health status to increase salience. The safer, equally accurate option was already on the list and was not chosen, and nothing was recorded in targeting_dropped. I want that on the record.
ON THE RECORDThe directive pool that produced 'Send this to any christopher you know' and 'Forward this to the shareholders in your life' is scraping proper nouns and role words out of the release without any semantic check. It got lucky this time. Someone should look at that generator before it turns a victim's or a prosecutor's name into a share prompt on a live alert.
ON THE RECORDThe advice is the weakest part of the artefact. Telling a frightened parent to ask a brand partner to 'name the published study' hands the seller an easy win — they will name something, and the parent will feel reassured by a citation they cannot evaluate. The FTC's whole case is that the substantiation is not there. The useful instruction is: do not let a supplement replace or delay treatment a clinician has prescribed, and take any product marketed as reducing a child's suicide risk to that clinician before buying. That is not what the draft says.
The sources
Official sourceFTC Sues to Stop Amare Global Holdings from Misrepresenting the Health Benefits of Its Dietary Supplements for Children and Adults2026-06-02
The FTC sued a multilevel marketer and three principals over claims that its children's and adult supplements could treat depression, anxiety and ADHD, and over earnings claims made to "brand partner" recruits.
Authority: official. Retrieved 2026-08-20.
Limitation: A press release about an unproven complaint; it gives no consumer loss totals, no number of affected buyers or recruits, and no court outcome.
Open the original source →Other checks
Published under standing founder pass (A9) — every claim source-mapped by the machine.
▼ What the machine checked
- ✓ Not a community submission.
- ✗ Draws on an FTC enforcement release, which names a defendant: "FTC Sues to Stop Amare Global Holdings from Misrepresenting the Health Benefits ".
- ✓ All 5 material sentence(s) map to FTC.
- ✗ anthropic returned "overstated"; groq returned "overstated"; openrouter recorded dissent — published on the receipt, not blocking (A9 amendment).
- ✓ No audience band is set.
No human affirmed these. They were verified by the classifier described in Amendment A9, on 2026-08-20.
Something wrong here? Tell us and we'll correct it — corrections are published, not quietly edited.
Phishy? Send it → sharelivefraud.com/squire-it
Not affiliated with any government agency, credit bureau, bank, platform, or law-enforcement agency. Informational only — not legal or financial advice.
Naming a source is not an endorsement, and being named here is not an accusation against any company.
Powered by SquireIt™
Verify this receipt at squireit.com